| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 33 | JP 3 | 99.78 |
| Adipose Tissue and Metabolism | Lifetime | 76 | JP 4 | 99.74 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 49 | JP 4 | 99.39 |
| Biomarkers in Disease Mechanisms | Lifetime | 12 | JP 2 | 98.74 |
| Cardiovascular Disease and Adiposity | Lifetime | 90 | JP 4 | 99.45 |
| Lipid metabolism and disorders | Lifetime | 43 | JP 2 | 99.19 |
| Cholesterol and Lipid Metabolism | Lifetime | 73 | JP 2 | 98.79 |
| Pancreatic function and diabetes | Lifetime | 342 | JP 11 | 98.93 |
| Metabolism, Diabetes, and Cancer | Lifetime | 366 | JP 10 | 98.58 |
| Diabetes Treatment and Management | Lifetime | 443 | JP 17 | 98.35 |
| Lipid metabolism and biosynthesis | Lifetime | 233 | JP 12 | 97.49 |
| Regulation of Appetite and Obesity | Lifetime | 377 | JP 22 | 97.73 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 531 | JP 14 | 98.29 |
| Diabetes Management and Research | Lifetime | 879 | JP 22 | 97.27 |
| Pharmacology and Obesity Treatment | Lifetime | 959 | JP 12 | 90.95 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 141 | JP 7 | 95.06 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 178 | JP 5 | 93.30 |
| Diabetes Treatment and Management | 2021-2025 | 439 | JP 14 | 95.33 |
| Adipose Tissue and Metabolism | 2021-2025 | 424 | JP 9 | 92.10 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 183 | JP 3 | 90.61 |
| Diabetes Management and Research | 2021-2025 | 502 | JP 7 | 94.44 |
| Pancreatic function and diabetes | 2021-2025 | 464 | JP 14 | 92.55 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 348 | JP 22 | 80.40 |
| Adrenal and Paraganglionic Tumors | 2021-2025 | 674 | JP 41 | 80.60 |
| Diabetes Management and Education | 2021-2025 | 943 | JP 10 | 73.09 |
| Vitamin C and Antioxidants Research | 2021-2025 | 553 | JP 10 | 63.95 |
| Pharmacology and Obesity Treatment | 2021-2025 | 695 | JP 11 | 66.11 |
| Lipid metabolism and disorders | 2021-2025 | 841 | JP 37 | 61.85 |
